Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Mam Holdings Of West Florida L L C currently faces 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are assigned to 2 distinct art units, suggesting that the company's research is concentrated in a few specific technical niches within the broader life sciences field. The use of 2 distinct art units implies that the company must be prepared for different examination standards even within the Biotechnology & Pharmaceuticals sector. This level of activity, with 3 pending office actions, indicates an ongoing effort to secure patent protection.
The portfolio is being reviewed by 3 distinct examiners, ensuring that each of the 3 pending office actions is under the scrutiny of a different official. JACKSON III, WALTER is the busiest examiner for the company, currently managing 1 pending office action. Because there are 3 distinct examiners involved, no single examiner's habits or preferences will have a disproportionate impact on the overall portfolio. The distribution of 3 pending office actions among 3 distinct examiners across 2 distinct art units highlights a decentralized prosecution environment for the company's current Biotechnology & Pharmaceuticals filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
| PYLA, EVELYN Y | 1 | 55.8% | +47.1% |
| MCCORMICK, CATHERINE LYNN | 1 | 52.3% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17977476 | MESENCHYMAL STEM CELLS FOR THE PREVENTION AND TARGETED TREATMENT OF CANCER AND OTHER DISORDERS | MCCORMICK, CATHERINE LYNN | 45d overdue |
| 18607107 | MESENCHYMAL STEM CELL-DERIVED EXOSOME DRUG DELIVERY FOR CANCER AND OTHER DISORDERS | JACKSON III, WALTER | — |
| 18543748 | METHODS AND COMPOSITIONS FOR TREATING OCULAR GRAFT VERSUS HOST DISEASE AND OTHER OCULAR CONDITIONS | PYLA, EVELYN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17977476 | MESENCHYMAL STEM CELLS FOR THE PREVENTION AND TARGETED TREATMENT OF CANCER AND OTHER DISORDERS | MCCORMICK, CATHERINE LYNN | 45d overdue |
| 18543748 | METHODS AND COMPOSITIONS FOR TREATING OCULAR GRAFT VERSUS HOST DISEASE AND OTHER OCULAR CONDITIONS | PYLA, EVELYN Y | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18607107 | MESENCHYMAL STEM CELL-DERIVED EXOSOME DRUG DELIVERY FOR CANCER AND OTHER DISORDERS | JACKSON III, WALTER | 1638 | §102§103 | Final Rejection | — | Pending | Mar 15, 2024 |
| 18543748 | METHODS AND COMPOSITIONS FOR TREATING OCULAR GRAFT VERSUS HOST DISEASE AND OTHER OCULAR CONDITIONS | PYLA, EVELYN Y | 1633 | §102§103§112Other | Non-Final OA | — | Pending | Dec 18, 2023 |
| 17977476 | MESENCHYMAL STEM CELLS FOR THE PREVENTION AND TARGETED TREATMENT OF CANCER AND OTHER DISORDERS | MCCORMICK, CATHERINE LYNN | 1638 | §102§103 | Non-Final OA | 45d overdue | Pending | Oct 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMam Holdings Of West Florida L L C has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Walter Jackson III has the most, with 1 of Mam Holdings Of West Florida L L C's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
